Free Trial
Gary Nachman

Gary Nachman Analyst Performance

Biotech/BioPharma Equity Research Analyst at Canaccord Genuity Group

Gary Nachman is a stock analyst at Canaccord Genuity Group in the medical sector, covering 16 publicly traded companies. Over the past year, Gary Nachman has issued 24 stock ratings, including strong buy, buy, and hold recommendations. While full access to Gary Nachman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gary Nachman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
52 Last 9 Years
Buy Recommendations
74.51% 38 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy15.7%8 ratings
Buy58.8%30 ratings
Hold19.6%10 ratings
Sell5.9%3 ratings

Out of 51 total stock ratings issued by Gary Nachman at Canaccord Genuity Group, the majority (58.8%) have been Buy recommendations, followed by 19.6% Hold, 15.7% Strong Buy, and 5.9% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
81.3% of companies on NASDAQ
13 companies
NYSE
18.8% of companies on NYSE
3 companies

Gary Nachman, an analyst at Canaccord Genuity Group, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
16 companies
100.0%

Gary Nachman of Canaccord Genuity Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
56.3%
MED - DRUGS
2 companies
12.5%
LARGE CAP PHARMA
1 company
6.3%
MEDICAL SERVICES
1 company
6.3%
MED PRODUCTS
1 company
6.3%
PHARMACEUTICAL PREPARATIONS
1 company
6.3%
MED - GENERIC DRG
1 company
6.3%

Gary Nachman's Ratings History at Canaccord Genuity Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
AbbVie Inc. stock logo
ABBV
AbbVie
4/30/2026Boost Price Target$211.66$265.00Buy
AbbVie Inc. stock logo
ABBV
AbbVie
4/20/2026Initiated Coverage$204.08$262.00Buy
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4/20/2026Initiated Coverage$47.80$62.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4/20/2026Initiated Coverage$74.87$110.00Buy
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4/20/2026Initiated Coverage$10.88$21.00Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
4/20/2026Set Price Target$4.25$13.00Buy
Amgen Inc. stock logo
AMGN
Amgen
4/20/2026Initiated Coverage$350.16$366.00Hold
AbbVie Inc. stock logo
ABBV
AbbVie
4/20/2026Upgrade$204.95Strong-Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
4/20/2026Upgrade$4.21Strong-Buy
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4/20/2026Upgrade$10.78Strong-Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4/20/2026Upgrade$74.78Strong-Buy
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4/20/2026Upgrade$48.10Strong-Buy
AbbVie Inc. stock logo
ABBV
AbbVie
11/3/2025Set Price Target$218.14$256.00
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
10/30/2025Reiterated Rating$15.39$19.00Outperform
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
10/30/2025Reiterated Rating$73.57$89.00Strong-Buy
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
10/20/2025Reiterated Rating$36.63$50.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
10/17/2025Reiterated Rating$226.77$250.00Outperform
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
9/22/2025Set Price Target$61.36$75.00Strong-Buy
Amgen Inc. stock logo
AMGN
Amgen
9/3/2025Initiated Coverage$286.07Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
8/25/2025Reiterated Rating$207.74Outperform
Veru Inc. stock logo
VERU
Veru
8/13/2025Lower Price Target$3.17$20.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
8/1/2025Boost Price Target$189.02$236.00Outperform
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
7/31/2025Boost Price Target$30.98$40.00Outperform
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
7/31/2025Boost Price Target$43.35$64.00Strong-Buy
AbbVie Inc. stock logo
ABBV
AbbVie
2/3/2025Reiterated Rating$183.90$220.00Outperform